Design and Evaluation of Novel Radiolabelled VIP Derivatives for Tumour Targeting

Rangger C., Helbok A., Ocak M., Radolf T., Andreae F., Virgolini I. I., ...Daha Fazla

ANTICANCER RESEARCH, cilt.33, sa.4, ss.1537-1546, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 4
  • Basım Tarihi: 2013
  • Dergi Adı: ANTICANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1537-1546
  • Anahtar Kelimeler: Vasoactive intestinal peptide, VIP, radiolabelling, neuroendocrine tumours, tumour targeting, VASOACTIVE-INTESTINAL-PEPTIDE, BIOLOGICAL-ACTIVITY, VPAC(1) RECEPTOR, IN-VIVO, BREAST-CANCER, IMAGING AGENT, ANALOGS, BINDING, SOMATOSTATIN, POLYPEPTIDE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Vasoactive intestinal peptide (VIP) receptors are overexpressed in a broad variety of tumours. For the detection of these tumours, novel chemically modified and shortened VIP derivatives were designed. Materials and Methods: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-derivatised VIP analogues were radiolabelled with In-111 and in vitro and in vivo behaviour was evaluated using stability and internalisation assays, as well as an initial biodistribution study. Results: Radiolabelling of the VIP analogues resulted in high radiochemical yields, without need for further purification steps. Stability of the VIP derivatives was variable and cell uptake studies in VIP receptor-positive cell lines revealed that only a limited number of derivatives were internalised. In the tumour mouse model, no specific tumour targeting was shown. Conclusion: Since the tested VIP derivatives exhibited impaired in vitro and in vivo characteristics alternative modifications to increase their stability while retaining receptor affinity should be considered to enable the use of synthetic VIP analogues for tumour targeting.